1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Aptamer Group Plc

Aptamer Group Plc

LLSE:APTA
0.32
GBX
0.00
(0.00%)
3.15BMarket Cap
Apr 01Next Earn
2019 Y
2020 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
0.01
0.06
0.03
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
-0.03
-0.11
-0.01
- -
- -
Free Cash Flow per Basic Share
-0.01
- -
-0.04
-0.09
-0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
- -
0.12
- -
- -
- -
- -
Tangible Book Value per Share
0.01
- -
0.11
- -
- -
- -
- -
Basic Weighted Avg Shares
69
69
65
69
415
1,794
2,312
Sales/Revenue/Turnover
1
1
4
2
1
1
- -
Operating Margin (%)
-54.75
-107.9
-63.83
-465.58
-363.95
-219.87
- -
Depreciation Expense
- -
- -
- -
3
- -
- -
- -
Net Income, GAAP
- -
-1
-2
-8
-3
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-46.11
-78.96
-51.86
-447.26
-343.95
-201.5
- -
Working Capital
1
- -
7
- -
- -
1
1
LT Debt
- -
- -
1
1
1
- -
- -
Total Equity
1
- -
8
- -
1
1
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-117.79
-50.45
-187.58
-496.73
-213.66
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,988
1,991
2,927
Market Capitalization
7
8
31

Working Capital

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
Total Current Assets
3
2
3
Cash, Cash Equivalents & STI
2
1
2
Accounts Receivable, Net
1
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
650.81%
55.81%
Free Cash Flow
- -
203.31%
-15.38%
Net Income, GAAP
- -
90.52%
-18.05%
Sales/Revenue/Turnover
- -
58.26%
39.88%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
1
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Arron Tolley
Full Time Employees
30
Sector
Health technology
Industry
Biotechnology
Address
Windmill House York NY United Kingdom YO10 5BR
IPO Date
Dec 22, 2021
Website
aptamergroup.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Aptamer Group plc develops advanced synthetic binding agents for various applications across research, diagnostics, and therapeutics globally. The company leverages its proprietary Optimer® platform to engineer next-generation affinity reagents designed to overcome limitations often associated with conventional antibodies. These Optimer binders offer superior specificity, high stability, and accelerated development timelines, providing versatile solutions to bioprocessing experts, diagnostic developers, and pharmaceutical researchers. Through its tailored services, Aptamer Group assists pharmaceutical enterprises, diagnostic firms, and academic institutions worldwide in discovering and optimizing binders for complex targets. Recent advancements include the Optimer+ platform, which delivers enhanced binding affinity and quicker development, and a growing portfolio of licensing agreements, such as royalty deals for Alzheimer's diagnostics and vaccine adjuvants. Established in 2008 and headquartered in York, United Kingdom, the company continues to expand its commercial partnerships and revenue streams, including contracts with leading global pharmaceutical companies for biomarker research and targeted therapies.